Volume | 83,278 |
|
|||||
News | - | ||||||
Day High | 4.88 | Low High |
|||||
Day Low | 4.50 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Eagle Pharmaceuticals Inc | EGRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.60 | 4.50 | 4.88 | 4.75 | 4.57 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
985 | 83,278 | $ 4.74 | $ 394,961 | - | 3.95 - 30.40 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:50:06 | 2 | $ 4.74 | USD |
Eagle Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
61.82M | 12.99M | - | 316.61M | 35.64M | 2.74 | 1.73 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Eagle Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EGRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.05 | 4.88 | 3.95 | 4.32 | 125,376 | 0.70 | 17.28% |
1 Month | 4.96 | 5.26 | 3.95 | 4.56 | 137,969 | -0.21 | -4.23% |
3 Months | 5.53 | 6.81 | 3.95 | 5.28 | 149,800 | -0.78 | -14.10% |
6 Months | 14.29 | 14.29 | 3.95 | 5.55 | 225,643 | -9.54 | -66.76% |
1 Year | 28.89 | 30.40 | 3.95 | 10.87 | 191,214 | -24.14 | -83.56% |
3 Years | 40.54 | 58.25 | 3.95 | 27.79 | 153,257 | -35.79 | -88.28% |
5 Years | 57.71 | 64.94 | 3.95 | 36.55 | 151,673 | -52.96 | -91.77% |
Eagle Pharmaceuticals Description
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration. |